Secrecy. 28.1 With regard to confidential information ("Data"), which can be oral or written or both, received from The Regents regarding this Invention, the Licensee agrees:
Appears in 6 contracts
Samples: Certain (Scientific Learning Corp), Certain (Scientific Learning Corp), Certain (Scientific Learning Corp)
Secrecy. 28.1 With regard to confidential information ("Data"), which can be oral or written or both, received from The Regents regarding this Inventionthese Inventions, or received from the Licensee regarding its business, the Licensee receiving party (hereinafter "Recipient") agrees:
Appears in 3 contracts
Samples: License Agreement (Signal Pharmaceuticals Inc), License Agreement (Signal Pharmaceuticals Inc), License Agreement (Signal Pharmaceuticals Inc)
Secrecy. 28.1 27.1 With regard to confidential information ("“Data"”), which can be oral or written or both, received from The Regents regarding this Inventionthe Inventions, the Licensee agrees:
Appears in 2 contracts
Samples: License Agreement (CytomX Therapeutics, Inc.), Exclusive License Agreement (Ceres Ventures, Inc.)
Secrecy. 28.1 29.1 With regard to confidential information ("Data"), which can be oral or written or both, received from The Regents regarding this Invention, the Licensee agrees:
Appears in 2 contracts
Samples: Exclusive License Agreement (Regenicin, Inc.), License Agreement (Dynavax Technologies Corp)
Secrecy. 28.1 30.1 With regard to confidential information ("“Data"”), which can be oral or written or both, received from The Regents regarding this Inventionthe Inventions, the Licensee agrees:
Appears in 2 contracts
Samples: Exclusive License Agreement (Salmedix Inc), Exclusive License Agreement (Salmedix Inc)
Secrecy. 28.1 29.1 With regard to confidential information ("“Data"”), which can be oral or written or both, received from The Regents regarding this InventionInventions, the Licensee agrees:
Appears in 2 contracts
Samples: Exclusive License Agreement (Macropore Inc), Exclusive License Agreement (Cytori Therapeutics, Inc.)
Secrecy. 28.1 29.1 With regard to confidential information ("Data"), which with can be oral or written or both, received from The Regents regarding this Invention, the Licensee agrees:
Appears in 2 contracts
Samples: Exclusive License Agreement (Atherogenics Inc), Exclusive License Agreement (Atherogenics Inc)
Secrecy. 28.1 29.1 With regard to confidential information ("“Data"”), which can be oral or written or both, received from The Regents regarding this Invention, the Licensee agrees:
Appears in 1 contract
Secrecy. 28.1 26.1 With regard to confidential information ("Data"), which can be oral or written or both, received from The Regents regarding this Inventionthe Inventions, the Licensee agrees:
Appears in 1 contract
Secrecy. 28.1 29.1 With regard to confidential information ("“Data"”), which can be received in oral or and/or written or bothform, received from The Regents regarding this Inventionthese Inventions, the Licensee agrees:
Appears in 1 contract
Secrecy. 28.1 29.1 With regard to confidential information ("Data"), which can be oral or written or both, received from The Regents regarding this Invention, the Licensee agrees:
Appears in 1 contract
Secrecy. 28.1 29.1 With regard to confidential information ("“Data"”), which can be oral or written or both, received from The Regents regarding this Invention, the Licensee agrees:
Appears in 1 contract
Secrecy. 28.1 30.1 With regard to confidential information ("Data"), which can be oral or written or both, received from The Regents regarding this Invention, the Licensee agrees:
Appears in 1 contract
